Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the <scp>REALI</scp> European pooled data analysis
Gla-300 was effective and safe in insulin-naïve individuals with T2D, regardless of DD. Improvement in HbA1c was greater when Gla-300 was initiated in participants with a DD of less than 4 years, although the difference between the groups was modest.
Authors
- Riccardo C. Bonadonna (ORCID: https://orcid.org/0000-0002-9809-1005)
- Dı́dac Mauricio (ORCID: https://orcid.org/0000-0002-2868-0250)
- Celine Mauquoi
- Nick Freemantle (ORCID: https://orcid.org/0000-0001-5807-5740)
- Pierre Gourdy (ORCID: https://orcid.org/0000-0002-5362-3813)
- Mireille Bonnemaire
- Dirk Müller‐Wieland (ORCID: https://orcid.org/0000-0002-8807-6442)
- Carine Vera
Institutions
- University of Parma (IT)
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Hospital de Sant Pau (ES)
- Sanofi (France) (FR)
- MRC Clinical Trials Unit at UCL (GB)
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Institut des Arts de Diffusion (BE)
- Universitätsklinikum Aachen (DE)
- Ospedale di Parma (IT)
- Institut des Maladies Métaboliques et Cardiovasculaires (FR)
- University College London (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1111/dom.16008
- Citations
- 1
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- Sanofi